Erratum to: A multicentre trial of bucillamine in the treatment of early rheumatoid arthritis (SNOW study)

In Tables 4 and 5 and Fig. 1, and in the corresponding sections in the text, there were errors in the values for the simple disease activity index (SDAI) due to revision of the VAS scale calculation method (changed from mm to cm). The trend and the conclusion of these results are not changed by this revision, however. Corrected Tables 4 and 5 and Fig. 1 are shown on the following page. The corrected sections in the text are shown with underlining: ‘‘A similar EULAR (DAS28-CRP) improvement rate of 75.8% was seen after 12 months of treatment, and 76.4% after 24 months, and 57.7 and 64.3%, respectively, for SDAI (Table 5).’’ (In the Results, Clinical assessment section) ‘‘In this study, the 12and 24-month moderate or good response rate according to the EULAR criteria were 75.8 and 76.4% for DAS28 (CRP), 80.0 and 87.5% for DAS28 (ESR) and 57.7 and 64.3% for SDAI.’’ (In the Discussion, Comparison with previous studies conducted at other institutes [effectiveness as first-choice therapy] section) ‘‘Similarly, the DAS28 (ESR) and SDAI response rates were 87.5 and 64.3%, respectively.’’ (In Conclusions) The authors apologize for these errors.